UA88166C2 - Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания - Google Patents

Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания

Info

Publication number
UA88166C2
UA88166C2 UAA200613472A UAA200613472A UA88166C2 UA 88166 C2 UA88166 C2 UA 88166C2 UA A200613472 A UAA200613472 A UA A200613472A UA A200613472 A UAA200613472 A UA A200613472A UA 88166 C2 UA88166 C2 UA 88166C2
Authority
UA
Ukraine
Prior art keywords
tremor
peptide compounds
syndromes
treating essential
essential tremor
Prior art date
Application number
UAA200613472A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Томас Штьор
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of UA88166C2 publication Critical patent/UA88166C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UAA200613472A 2004-06-24 2005-06-22 Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания UA88166C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24

Publications (1)

Publication Number Publication Date
UA88166C2 true UA88166C2 (ru) 2009-09-25

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200613472A UA88166C2 (ru) 2004-06-24 2005-06-22 Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания

Country Status (19)

Country Link
US (1) US7427601B2 (enExample)
EP (1) EP1758606A1 (enExample)
JP (1) JP5038892B2 (enExample)
KR (1) KR20070034477A (enExample)
CN (1) CN1964733B (enExample)
AR (1) AR049940A1 (enExample)
AU (1) AU2005256468B2 (enExample)
BR (1) BRPI0512622A (enExample)
CA (1) CA2566301C (enExample)
EA (1) EA013592B1 (enExample)
IL (1) IL179732A0 (enExample)
MX (1) MXPA06015010A (enExample)
MY (1) MY146509A (enExample)
NO (1) NO20070423L (enExample)
NZ (1) NZ551207A (enExample)
TW (1) TWI361693B (enExample)
UA (1) UA88166C2 (enExample)
WO (1) WO2006000397A1 (enExample)
ZA (1) ZA200609021B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
CA2672494A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
CA2774569A1 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
MX2013005974A (es) 2010-12-02 2013-07-29 Ucb Pharma Gmbh Formulacion de lacosamida de administracion una vez al dia.
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DK1311256T3 (da) * 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
AU2003283958A1 (en) * 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
CA2544467C (en) 2002-11-18 2014-02-18 John M. Stewart Paralytic peptide for use in neuromuscular therapy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
CA2566301C (en) 2011-06-14
TWI361693B (en) 2012-04-11
CN1964733A (zh) 2007-05-16
EA200700108A1 (ru) 2007-06-29
EP1758606A1 (en) 2007-03-07
KR20070034477A (ko) 2007-03-28
MXPA06015010A (es) 2007-03-26
CA2566301A1 (en) 2006-01-05
MY146509A (en) 2012-08-15
NZ551207A (en) 2010-07-30
EA013592B1 (ru) 2010-06-30
CN1964733B (zh) 2012-05-23
WO2006000397A1 (en) 2006-01-05
JP5038892B2 (ja) 2012-10-03
US20050288234A1 (en) 2005-12-29
AR049940A1 (es) 2006-09-13
AU2005256468A1 (en) 2006-01-05
ZA200609021B (en) 2008-04-30
BRPI0512622A (pt) 2008-03-25
NO20070423L (no) 2007-03-22
AU2005256468B2 (en) 2010-12-09
US7427601B2 (en) 2008-09-23
IL179732A0 (en) 2007-05-15
JP2008503533A (ja) 2008-02-07
TW200603823A (en) 2006-02-01

Similar Documents

Publication Publication Date Title
UA88166C2 (ru) Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
TW200701982A (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia
TW200640924A (en) VEGF-R2 inhibitors and methods
TW200626068A (en) Active compounds for seed treatment
WO2006130399A3 (en) Therapeutic combinations and methods including irm compounds
WO2006063048A3 (en) Ibudilast for treating neuropathic pain and associated syndromes
UA86808C2 (ru) Применение пептидных соединений для лечения дискинезии
UA87843C2 (ru) Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
MX2007003032A (es) Analogos de loxapina y metodos de uso de los mismos.
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
TW200630367A (en) Substituted adenines and the uses thereof
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
ECSP056174A (es) Acidos hidroxamicos utiles en el tratamiento detrastornos hiperproliferativos
MY141002A (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia
TW200603801A (en) Novel dialkoxy-imidazopyridines
DK1569650T3 (da) Anvendelse af levocetirizin til behandling af vedvarende rhinitis allergica
NO20070128L (no) Ny anvendelse av peptidforbindelser for behandling av smerte i trigeminal neuralgi
TW200613301A (en) Novel amino-halogen-imidazopyridines
HK1099231A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
TW200701985A (en) Use of peptidic compounds for the prophylaxis and treatment of chronic headache